Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

Inclusion Criteria: Prior subretinal administration of LX101 (unilateral) ≥ 6 years old Signed written informed consent Exclusion Criteria: Prior gene therapy except LX101 Active intraocular or periocular infections Lacking of sufficient surviving retinal cells Prior ocular surgery within six months Retinoid like compounds or precursors were taken within three months Complicating systemic diseases Clinically significant abnormal baseline laboratory values Using of any retinal toxic compounds